Novo’s race to catch Eli Lilly may already be lost
A year ago, the rivalry between Eli Lilly and Novo was the fiercest in the industry. Now, it looks increasingly one-sided. The best evidence might be investors' reactions to each company's third-quarter results. Both stocks ...
We haven't written up this one. Endpoints News has the full story — the link below goes straight to it.